Summary
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc.; CANbridge Life Sciences, Ltd.; Biogen Idec International GmbH; St. Vincent's Hospital Sydney Limited; and Kyowa Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
History
AVEO Oncology was founded in 2001 in Cambridge, Massachusetts. The company initially focused on discovering and developing novel drugs based on a genetic platform for the treatment of cancer, with a focus on oncology and rare diseases. The company has since expanded its portfolio to include programs targeting autoimmune, metabolic and inflammatory diseases as well as immuno-oncology.
Mission
AVEO Oncology’s mission is to discover and develop targeted therapies that improve the lives of patients with cancer, autoimmune, and other serious diseases.
Vision
AVEO Oncology’s vision is to be a leader in the development of targeted therapies that have the potential to improve the lives of patients with cancer, autoimmune, and other serious diseases.
Key Team
Mr. Jeb Ledell (Chief Operating Officer)
Dr. Emile Farhan Ph.D. (Sr. VP of Technical Operations)
Ms. Danielle Holland (VP of Legal & Corp. Sec.)
Mr. Kevin Peacock (Sr. VP of Marketing)
Mr. David Crist (VP of Sales)
Ms. Catherine DeRose (VP of HR)
Ms. Lisa M. Bruneau (VP of Fin. & Treasurer)
Recognition and Awards
AVEO has been recognized with numerous awards and accolades, including being named among the top 50 FDA Approval Watch Companies, the 2008 Mass High Tech All-Star Award, and the 2009 Biotech Business Leader Award.
References
